Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03862222 · ClinicalTrials.gov registry record

Atlas of Retinal Imaging in Alzheimer's Study

A clinical trial, sponsored by University of Rhode Island.

Completed
Registry status
165
Enrollment target

NCT03862222 is a clinical trial that has completed, run by University of Rhode Island. The registered enrollment target is 165 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03862222 has completed, sponsored by University of Rhode Island.

COMPLETED
Registry status
165 participants
Enrollment target

Study Summary

The Atlas of Retinal Imaging in Alzheimer's (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer's disease (AD). The objective of this project is to create a 'gold standard' reference database of structural anatomic and functional imaging of the retina, in order to enable the identification and development of both sensitive and reliable markers of AD risk and/or progression. Our ultimate goal is to develop a new screening protocol that identifies changes related to AD 10-20 years before AD is clinically visible.

Interventions

  • OTHER Retinal Imaging
  • OTHER Pupillometry
  • OTHER Contrast Sensitivity
  • DIAGNOSTIC_TEST Neuropsychological Evaluation
  • GENETIC APOE genotyping

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2019-12-16
Est. Completion 2025-05-31

Sponsor

University of Rhode Island

29 total trials

What the Registry Record Tells You About NCT03862222

The ClinicalTrials.gov registry entry for NCT03862222 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rhode Island, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Retinal Imaging is the first listed.

NCT03862222 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03862222 about?

NCT03862222 is a clinical study titled "Atlas of Retinal Imaging in Alzheimer's Study". The Atlas of Retinal Imaging in Alzheimer's (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer's disease (AD). The objective of this project is to create a 'gold standard' refe...

What is the current status of trial NCT03862222?

This trial is currently completed. The enrollment target is 165 participants. The study started on 2019-12-16. Estimated completion is 2025-05-31.

What interventions are being tested in trial NCT03862222?

The interventions under investigation include: Retinal Imaging (OTHER), Pupillometry (OTHER), Contrast Sensitivity (OTHER), Neuropsychological Evaluation (DIAGNOSTIC_TEST), APOE genotyping (GENETIC).

Who is sponsoring clinical trial NCT03862222?

This trial is sponsored by University of Rhode Island, which has 29 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.